
Leigh C. Maier
Examiner (ID: 4240, Phone: (571)272-0656 , Office: P/1673 )
| Most Active Art Unit | 1623 |
| Art Unit(s) | 1673, 1693, 1614, 1623, 1621 |
| Total Applications | 1395 |
| Issued Applications | 727 |
| Pending Applications | 80 |
| Abandoned Applications | 594 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17988845
[patent_doc_number] => 20220354882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => TREATMENT OF MYELOSUPPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/550942
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550942
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/550942 | TREATMENT OF MYELOSUPPRESSION | Dec 13, 2021 | Abandoned |
Array
(
[id] => 17609809
[patent_doc_number] => 20220152088
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/546880
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82529
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546880
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/546880 | Complexing agent salt formulations of pharmaceutical compounds | Dec 8, 2021 | Issued |
Array
(
[id] => 17458728
[patent_doc_number] => 20220072032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/532414
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532414
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532414 | INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | Nov 21, 2021 | Abandoned |
Array
(
[id] => 17640603
[patent_doc_number] => 20220168341
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => COMPOSITIONS AND METHODS OF TREATING DRY EYE SYNDROME AND OTHER TRAUMATIZED NON-KERATINIZED EPITHELIAL SURFACES
[patent_app_type] => utility
[patent_app_number] => 17/454117
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22994
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17454117
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/454117 | Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces | Nov 8, 2021 | Issued |
Array
(
[id] => 18886368
[patent_doc_number] => 11865124
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-09
[patent_title] => Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS)
[patent_app_type] => utility
[patent_app_number] => 17/522244
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 33
[patent_no_of_words] => 5836
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522244
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522244 | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS) | Nov 8, 2021 | Issued |
Array
(
[id] => 17426823
[patent_doc_number] => 20220054531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => TREATMENT OF ACUTE MYELOID LEUKEMIA WITH HYPOMETHYLATING AGENTS AND 2-O, 3-O DESULFATED HEPARINOIDS
[patent_app_type] => utility
[patent_app_number] => 17/519298
[patent_app_country] => US
[patent_app_date] => 2021-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -100
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519298
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/519298 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH HYPOMETHYLATING AGENTS AND 2-O, 3-O DESULFATED HEPARINOIDS | Nov 3, 2021 | Abandoned |
Array
(
[id] => 17519277
[patent_doc_number] => 20220105125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => AGENT FOR IMPROVING OCULAR SUBJECTIVE SYMPTOMS AND METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/509576
[patent_app_country] => US
[patent_app_date] => 2021-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17509576
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/509576 | Agent for improving ocular subjective symptoms and method thereof | Oct 24, 2021 | Issued |
Array
(
[id] => 19258054
[patent_doc_number] => 12018098
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-25
[patent_title] => Method for producing depolymerized cellulose ether
[patent_app_type] => utility
[patent_app_number] => 17/505920
[patent_app_country] => US
[patent_app_date] => 2021-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5017
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17505920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/505920 | Method for producing depolymerized cellulose ether | Oct 19, 2021 | Issued |
Array
(
[id] => 19624097
[patent_doc_number] => 12162901
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => N-acetylated sialic acids and related sialosides
[patent_app_type] => utility
[patent_app_number] => 17/491518
[patent_app_country] => US
[patent_app_date] => 2021-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 17
[patent_no_of_words] => 31039
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17491518
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/491518 | N-acetylated sialic acids and related sialosides | Sep 29, 2021 | Issued |
Array
(
[id] => 19608913
[patent_doc_number] => 12157779
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-03
[patent_title] => Cyclodextrin dimers, compositions thereof, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/461069
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 179
[patent_figures_cnt] => 192
[patent_no_of_words] => 44699
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461069
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/461069 | Cyclodextrin dimers, compositions thereof, and uses thereof | Aug 29, 2021 | Issued |
Array
(
[id] => 18915764
[patent_doc_number] => 11878030
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Ophthalmic formulations comprising cooperative complexes of low- and high-molecular-weight hyaluronic acid
[patent_app_type] => utility
[patent_app_number] => 17/458798
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5742
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458798 | Ophthalmic formulations comprising cooperative complexes of low- and high-molecular-weight hyaluronic acid | Aug 26, 2021 | Issued |
Array
(
[id] => 19311617
[patent_doc_number] => 12037420
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Dextran-poly alpha-1,3-glucan graft copolymers and synthesis methods thereof
[patent_app_type] => utility
[patent_app_number] => 17/412880
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 23966
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412880
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/412880 | Dextran-poly alpha-1,3-glucan graft copolymers and synthesis methods thereof | Aug 25, 2021 | Issued |
Array
(
[id] => 17426822
[patent_doc_number] => 20220054530
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOUNDS FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/403102
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16152
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403102
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403102 | COMPOUNDS FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | Aug 15, 2021 | Abandoned |
Array
(
[id] => 17356851
[patent_doc_number] => 20220017647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => CHITOSAN-DERIVED COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/397579
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/397579 | Chitosan-derived compositions | Aug 8, 2021 | Issued |
Array
(
[id] => 18931032
[patent_doc_number] => 11883426
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Treatment for methamphetamine cardiovascular disease
[patent_app_type] => utility
[patent_app_number] => 17/397973
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 44
[patent_no_of_words] => 15897
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397973
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/397973 | Treatment for methamphetamine cardiovascular disease | Aug 8, 2021 | Issued |
Array
(
[id] => 19150129
[patent_doc_number] => 11975019
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Sulfated glycosaminoglycan biomaterials as proteoglycan mimics
[patent_app_type] => utility
[patent_app_number] => 17/372102
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 19360
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372102
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/372102 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | Jul 8, 2021 | Issued |
Array
(
[id] => 17297824
[patent_doc_number] => 20210393663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR OR ITS ANALOG FOR INHALATION
[patent_app_type] => utility
[patent_app_number] => 17/354702
[patent_app_country] => US
[patent_app_date] => 2021-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354702
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/354702 | PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR OR ITS ANALOG FOR INHALATION | Jun 21, 2021 | Abandoned |
Array
(
[id] => 17586523
[patent_doc_number] => 11324765
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Inhibiting inflammation with milk oligosaccharides
[patent_app_type] => utility
[patent_app_number] => 17/333614
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 3320
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333614
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/333614 | Inhibiting inflammation with milk oligosaccharides | May 27, 2021 | Issued |
Array
(
[id] => 17213088
[patent_doc_number] => 20210346424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO
[patent_app_type] => utility
[patent_app_number] => 17/321677
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17321677
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/321677 | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto | May 16, 2021 | Issued |
Array
(
[id] => 17050561
[patent_doc_number] => 20210259995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS
[patent_app_type] => utility
[patent_app_number] => 17/313639
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12933
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313639 | METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS | May 5, 2021 | Abandoned |